NCT02952898View on ClinicalTrials.gov

Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses

PHASE3CompletedINTERVENTIONAL
Enrollment

665

Participants

Timeline

Start Date

October 27, 2016

Primary Completion Date

July 11, 2017

Study Completion Date

September 6, 2017

Conditions
Actinic Keratosis
Interventions
DRUG

GDC 695

GDC 695 is a topical gel.

DRUG

Diclofenac Sodium Gel, 3%

Diclofenac sodium gel, 3% is an FDA-approved drug.

DRUG

Vehicle gel

Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.

Trial Locations (16)

23507

Site 28, Norfolk

29607

Site 04, Greenville

29621

Site 26, Anderson

33162

Site 01, North Miami Beach

33609

Site 12, Tampa

33756

Site 22, Clearwater

34471

Site 27, Ocala

46032

Site 05, Carmel

46168

Site 02, Plainfield

64506

Site 25, Saint Joseph

72916

Site 07, Fort Smith

87106

Site 21, Albuquerque

92117

Site 14, San Diego

94582

Site 24, San Ramon

99202

Site 10, Spokane

02886

Site 03, Warwick

All Listed Sponsors
lead

Balmoral Medical company

INDUSTRY

NCT02952898 - Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses | Biotech Hunter | Biotech Hunter